BIIB Q1 2018 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q1 2018 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.1B+11.4% YoY

Gross Profit

$2.7B85.8% margin

Operating Income

$1.5B49.0% margin

Net Income

$1.2B37.5% margin

EPS (Diluted)

$5.54

QoQ Revenue Growth

-5.3%

Cash Flow

Operating Cash Flow

$1.5B

Free Cash Flow

$1.3B

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$26.1B

Total Liabilities

$12.1B

Stockholders' Equity

$14.1B

Cash & Equivalents

$4.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.1B	$2.8B	+11.4%
Gross Profit	$2.7B	$2.4B	+10.7%
Operating Income	$1.5B	$1.0B	+49.8%
Net Income	$1.2B	$748M	+56.9%

Revenue Segments

Interferon

$550M40%

TYSABRI product

$462M34%

SPINRAZA

$364M26%

Geographic Segments

UNITED STATES

$1.5B61%

Non-US

$986M39%